Stockscreener 앱 받기
359.21
1.11%
-4.04
시간 외 거래:
359.12
-0.09
-0.03%
전일 마감가:
$363.25
열려 있는:
$363
하루 거래량:
362.08K
Relative Volume:
0.97
시가총액:
$16.04B
수익:
$2.76B
순이익/손실:
$1.11B
주가수익비율:
19.79
EPS:
18.15
순현금흐름:
$898.10M
1주 성능:
-10.30%
1개월 성능:
-2.50%
6개월 성능:
+30.97%
1년 성능:
+56.90%
1일 변동 폭
$355.79
$363.00
1주일 범위
$355.79
$406.42
52주 변동 폭
$208.62
$417.81
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| UTHR | 359.21 | 16.04B | 2.76B | 1.11B | 898.10M | 18.15 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Seizert Capital Partners LLC Raises Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Empowered Funds LLC Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy - Seeking Alpha
United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom - Seeking Alpha
Entropy Technologies LP Cuts Stock Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Chronic Pulmonary Hypertension Market Size in the 7MM was ~USD 28,290 million in 2023, estimates DelveInsight - The Globe and Mail
Chase Investment Counsel Corp Takes $492,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Insider Sale: Director Judy Olian Sells Shares of United Therape - GuruFocus.com
Unsatisfied With $70M UTC Win, Sandoz Appeals To 3rd Circ. - Law360
State of New Jersey Common Pension Fund D Sells 1,464 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Principal Financial Group Inc. - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Lowered by Los Angeles Capital Management LLC - MarketBeat
Fiera Capital Corp Makes New $517,000 Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $370.86 - MarketBeat
Galvin Gaustad & Stein LLC Invests $8.96 Million in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics president sells shares worth $9.97 million By Investing.com - Investing.com Canada
United Therapeutics president sells shares worth $9.97 million - Investing.com
United Therapeutics Stock Soars to All-Time High of $413.66 - Investing.com
Philip James Wealth Mangement LLC Invests $475,000 in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Summit Global Investments - MarketBeat
United Therapeutics (NASDAQ:UTHR) Sets New 1-Year HighStill a Buy? - MarketBeat
Financial Enhancement Group LLC Makes New $6.67 Million Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Amalgamated Bank Cuts Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Holdings Increased by National Pension Service - MarketBeat
United Therapeutics director Giltner sells shares worth $3.8 million - Investing.com
Insider Sale: Director Richard Giltner Sells 10,000 Shares of Un - GuruFocus.com
United Therapeutics director Giltner sells shares worth $3.8 million By Investing.com - Investing.com UK
Which GCs Sold Stock In Oct.? Broadcom, T-Mobile And More - Law360
1,331 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by HMS Capital Management LLC - MarketBeat
United Therapeutics CFO sells $2.49 million in stock - Investing.com
United Therapeutics CFO sells $2.49 million in stock By Investing.com - Investing.com UK
United Therapeutics to Present at UBS Healthcare Conference: Key Updates Coming | UTHR Stock News - StockTitan
United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
AlphaCentric Advisors LLC Sells 8,250 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) - GuruFocus.com
United Therapeutics Co. (NASDAQ:UTHR) Director Sells $192,081.30 in Stock - MarketBeat
Sandoz Wins $70M In Antitrust Suit Over Hypertension Drug - Law360
Sandoz's Award Cut to $71 Million in Generic-Remodulin UTC Case - Bloomberg Law
United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance UK
United Therapeutics Q3 Earnings & Sales Beat Estimates - MSN
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call Transcript - Insider Monkey
New York State Teachers Retirement System Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN
United Therapeutics stock soars to all-time high of $377.93 By Investing.com - Investing.com Canada
United Therapeutics (NASDAQ:UTHR) Price Target Raised to $302.00 at The Goldman Sachs Group - MarketBeat
United Therapeutics (NASDAQ:UTHR) Hits New 52-Week High on Analyst Upgrade - MarketBeat
United Therapeutics stock soars to all-time high of $377.93 - Investing.com
United Therapeutics shares rated Neutral by Ladenburg, target lifted on Tyvaso sales strength - Investing.com Australia
United Therapeutics shares target raised to $425 by H.C. Wainwright - Investing.com India
United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by AustralianSuper Pty Ltd - MarketBeat
United Therapeutics (NASDAQ:UTHR) Announces Quarterly Earnings Results, Beats Expectations By $0.23 EPS - MarketBeat
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Nov 11 '24 |
Sale |
407.32 |
15,000 |
6,109,841 |
0 |
| Olian Judy D. | Director |
Nov 11 '24 |
Sale |
412.48 |
1,750 |
721,840 |
5,655 |
| Mesa Nilda | Director |
Nov 08 '24 |
Sale |
412.28 |
224 |
92,350 |
5,783 |
7.22%
0.81%
자본화:
|
볼륨(24시간):